AZ sells rights to statin med Crestor to Grünenthal
Grünenthal will pay $320m upfront for the rights
Read More
Tag: Crestor
Generic competition hits AZ’ first-quarter sales
AstraZeneca’s first-quarter performance has taken a hit from generic competition to Crestor, but the firm says the results are no surprise and that it will swing back into the black this year.
Read More
Mixed first quarter fortunes for GSK, AZ
UK-based drug giants GlaxoSmithKline and AstraZeneca have reported a mixed bag of results for the first quarter of the year.
Read More
AZ books 12 percent sales fall for Q4
AstraZeneca has booked a drop in revenues for the fourth quarter but says 2017 could be a ‘turning point’ for the firm as it comes to the end of its patent-expiry phase and begins its return to growth.
Read More
AZ’ Q3 boosted by tax gains, currency benefits
AstraZeneca’s third-quarter net profit came in at 32 percent higher than a year ago, as a substantial one-time tax gain and currency exchange benefit helped weather falling sales during the period.
Read More
AZ files suit against FDA to prevent Crestor generics
AstraZeneca has filed a lawsuit to prevent the US Food and Drug Administration from approving the sale of generic versions of its multi-billion-dollar cholesterol drug Crestor.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
